The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
The partners will make a test for monitoring Tysabri available to clinicians and clinical trial partners through ResearchDx's reference laboratory.
The firm aims to integrate protein biomarker measurements, data from patient wearables, and imaging to improve treatment and management of multiple sclerosis.
In studies of 140 multiple sclerosis patients and controls, the researchers identified two blood-based metabolites as potential markers of the disease.
Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.
The test will now be offered along with another cell-based test to detect a number of diseases often misdiagnosed as multiple sclerosis.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
Numares will use its technology to advance work by Oxford researchers to create a noninvasive test to better diagnose MS.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.